Pricing Log in Create free account
Friday 6 November 2026 Export CTSO’s income statement to Excel — free account

Cytosorbents Corporation

CTSO Healthcare Medical Devices

Cytosorbents Corporation’s revenue for fiscal 2025 (year ended December 2025) was $37.1 million, up 4.12% from fiscal 2024.

Revenue
+0.17%
EPS
−333.3%
Free cash flow
+64.9%
Total debt
+19.9%

Quarter to June 2026, against a year earlier

4.75 0.15 +3.26%
Market cap
$14.5M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
3/9
Altman Z
−9.24
Beneish M
−2.11
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.27
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — 2 — — 4 — —
Sell — — — — — — — — — — — —
Insider Ownership 13.70%

Capital & Financial Ratios $m

Size
Market Cap 14.50
Revenue ttm 37.22
Net income ttm (18.21)
Free cash flow ttm (9.42)
Net debt Q 12.83
Valuation
P/E 0.00
Forward P/E (1.03) (negative: loss-making)
Price / sales 0.40
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.66 (below 1: weak)
Debt / equity Q (22.96) (negative: negative equity)
Interest coverage Q (3.04)
Growth
Revenue growth Q +0.17% (above 0%: growing)
Operating income growth Q +27.03% (above 0%: growing)
EPS, this year −72.18% (below 0%: weak)
EPS, next year A +84.74% (at or above 15%: strong)
Revenue, next year A +4.90%
EPS, past 5 yrs —
EPS, next 5 yrs A +45.95% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.7×, against a ten-year median of 5.9×; over the ten years it ranged from 0.7× in 2026 to 25.4× in 2016.
P/S against its own 10 years 0.92%
10-year low 10-year high
EV/Sales against its own 10 years 0.92%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 14 8 6 4
Receivables 6 7 8 7
Inventory 3 3 5 4
Other — — — —
25 22 21 16
2023 2024 2025 Q'26
Payables 4 3 3 2
ST’ Debt 3 — — 14
Other — — — —
14 10 10 24

Compound Annual Growth %

10y 5y 3y
Sales 22.70% (2.00%) 2.23%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (3.25%) (40.51%) (44.95%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.00 Actual −1.40

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.20 −0.80 Beat by 0.40
Q4 FY25 −1.00 −1.80 Miss by 0.80
Q1 FY26 −1.20 −1.60 Miss by 0.40
Q2 FY26 −1.00 −1.40 Miss by 0.40
Q3 FY26 −0.90 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.60) (1.40) — — —
’25 (0.49) 0.60 (1.00) (1.80) (2.60)
’24 (2.40) (1.60) (1.02) (2.80) (7.60)
’23 (3.40) (2.80) (4.20) (2.82) (13.10)
’22 (4.20) (5.00) (5.60) (0.35) (15.00)
’21 (2.00) (2.20) (3.00) (4.20) (11.40)
’20 (2.00) (1.60) (0.40) 0.00 (4.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 9 10 — — —
’25 9 10 9 9 37
’24 9 9 9 9 36
’23 9 9 9 3 31
’22 9 8 8 9 35
’21 11 12 10 11 43
’20 9 10 11 12 41
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (3) (2) (3) (5) (12)
’24 (5) (5) (2) (2) (14)
’23 (3) (7) (5) (6) (22)
’22 (8) (8) (7) (5) (28)
’21 (2) (2) (4) (5) (14)
’20 (3) 2 (3) (1) (6)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (1) — — —
’25 (4) (2) (3) (5) (13)
’24 (5) (5) (3) (2) (15)
’23 (4) (7) (5) (7) (23)
’22 (9) (13) (7) (6) (35)
’21 (3) (3) (5) (7) (18)
’20 (4) 1 (4) (1) (7)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 10 15 23 25 41 43 35 31 36 37 37 +16.3% 39 44 52 +11.7%
Gross margin, % 58.50 63.58 66.72 70.48 73.05 74.41 59.77 70.62 69.92 71.48 71.61 +13.0 pt
EBT (12) (9) (18) (20) (9) (25) (34) (30) (22) (9) (19) (3.7%)
EBT margin, % (126.81) (60.31) (79.23) (81.60) (21.86) (58.60) (97.74) (96.70) (62.96) (23.20) (50.01) +103.6 pt
Net income (12) (8) (17) (19) (8) (25) (33) (29) (21) (8) (18) (3.9%)
Per share, $
Per share, $ Revenue 7.49 10.97 14.65 15.47 21.13 19.91 15.92 13.92 13.08 11.91 11.85 +5.3%
Earnings (9.40) (6.40) (11.20) (12.00) (4.00) (11.40) (15.00) (13.10) (7.60) (2.60) (5.80) (13.3%)
Cash flow (5.29) (4.68) (7.06) (10.39) (2.89) (6.46) (12.96) (9.70) (5.30) (3.98) (2.91) (3.1%)
Capex (0.47) (1.22) (0.99) (0.94) (0.86) (1.97) (2.96) (0.42) (0.25) (0.13) (0.09) (13.0%)
Free cash flow (5.76) (5.89) (8.05) (11.33) (3.76) (8.43) (15.92) (10.12) (5.55) (4.11) (3.00) (3.7%)
Book value 1.05 7.43 11.03 2.12 40.81 28.86 16.24 10.52 4.08 1.90 (0.24) +6.8%
Shares, m 1 1 2 2 2 2 2 2 3 3 3 +10.5%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 15.08 11.94 11.03 4.98 7.55 4.21 2.29 1.54 1.39 1.07 0.40 6.1
P/B 107.44 17.62 14.66 36.33 3.91 2.90 2.24 2.03 4.46 6.74 0.00 19.8
EV/Sales 15.05 11.45 10.48 5.09 5.83 3.32 1.80 1.24 1.62 1.42 0.75 5.7
EV/FCF (19.57) (21.32) (19.08) (6.95) (32.79) (7.84) (1.79) (1.71) (3.83) (4.12) (2.94) (11.9)
Cash, $m
Cash, $m Operating cash flow (7) (6) (11) (17) (6) (14) (28) (22) (14) (12) (9) +7.0%
Capex (1) (2) (2) (2) (2) (4) (6) (1) (1) 0 0 (3.9%)
Free cash flow (7) (8) (12) (18) (7) (18) (35) (23) (15) (13) (9) +6.4%
Balance, $m
Balance, $m Working capital 4 13 21 11 72 51 24 11 12 11 (8) +13.3%
Net debt 0 (7) (12) 3 (70) (38) (17) (9) 6 10 13 n/m
Shareholders’ equity 1 10 17 3 79 63 35 23 11 6 (1) +17.9%
Returns, %
Returns, % ROA (112.31) (52.05) (59.04) (62.57) (13.36) (27.37) (42.96) (50.34) (41.30) (17.91) (42.38) +94.4 pt
ROIC (715.47) (209.74) (216.12) (190.11) (73.46) (58.59) (107.43) (138.73) (61.12) (56.48) (66.90) +659.0 pt
ROE (246.41) (151.66) (126.57) (189.32) (18.97) (34.64) (67.00) (99.38) (119.80) (96.39) (336.17) +150.0 pt
People
People Employees 65 84 125 153 195 221 198 186 149 129 — +7.9%
Revenue/emp, $m 0.15 0.18 0.18 0.16 0.21 0.20 0.18 0.17 0.24 0.29 — +7.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Cytosorbents Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ALUR Allurion Technologies, Inc. $16.7M — (loss-making) — (loss-making) −47.19% (below 0%: shrinking) n/m +65.98% (above 0%: growing) 41.70% (126.60%) Compare
LFWD Lifeward Ltd. $16.3M — (loss-making) — (loss-making) +15.71% (above 0%: growing) n/m −52.77% (below 0%: shrinking) 40.90% (62.69%) Compare
ARAY Accuray Incorporated $14.8M — (loss-making) — (loss-making) −7.90% (below 0%: shrinking) n/m −138.30% (below 0%: shrinking) 0.00% (42.19%) Compare
CTSO Cytosorbents Corporation $14.5M — (loss-making) — (loss-making) +0.17% (above 0%: growing) n/m +64.90% (above 0%: growing) 73.18% (27.39%)
RBOT Vicarious Surgical Inc. $14.3M — (loss-making) — — n/m +47.33% (above 0%: growing) 0.00% 0.00% Compare
HSCS HeartSciences Inc. $13.3M — (loss-making) — (loss-making) −46.15% (below 0%: shrinking) n/m +18.18% (above 0%: growing) 61.90% (139,957.14%) Compare
PETV PetVivo Holdings, Inc. $12.9M — (loss-making) — (loss-making) +13.48% (above 0%: growing) n/m +40.13% (above 0%: growing) 66.14% (476.54%) Compare
ITOC iTonic Holdings Ltd. $12.4M — — — — — — — Compare
PAVM PAVmed Inc. $12.4M — (loss-making) — (loss-making) +450.00% (above 0%: growing) n/m −125.63% (below 0%: shrinking) (269.70%) (21,278.79%) Compare
Median of peers $13.8M — — +2.79% — +18.18% 40.90% (126.60%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 25 June 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 808.43k 723.16k 11.73
2024 899.70k 953.14k 16.70
2023 1.33m 729.76k 20.37

Ownership

Directors and executive officers, together 7.80%
Avenir Corporation 6.50%
ROKK LLC P.O. Box 5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cytosorbents Corporation (CTSO) Latest News

29 Oct

Impact 3 · · PR Newswire

30 Sep

Impact 3 · · PR Newswire

23 Sep

Impact 3 ·

3 Sep

Impact 4 ·

2 Sep

Impact 4 ·

17 Aug

Impact 3 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript

6 Aug

Impact 3 ·

21 May

Impact 3 · · Zacks Small Cap Research

14 May

Impact 3 · · Moby transcript
Impact 3 · · GuruFocus.com

13 May

Impact 4 · transcript
Impact 3 · · PR Newswire

6 Apr

Impact 4 · · Zacks Small Cap Research

26 Mar

Impact 4 · · The Motley Fool transcript
Impact 4 · · Moby

25 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Associated Press Finance
Impact 4 · · PR Newswire

19 Mar

Impact 4 · · PR Newswire

14 Feb

Impact 3 · · Simply Wall St.

13 Jan

Impact 4 · · Zacks Small Cap Research

12 Jan

Impact 4 · · PR Newswire

17 Nov

Impact 4 · · Zacks Small Cap ResearchAssociated Press Finance
Impact 3 · · PR Newswire

14 Nov

Impact 4 · · GuruFocus.com

13 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · Associated Press Finance
stockrow.com/CTSO · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com